Work

Rituximab, Acalabrutinib, and Durvalumab for Primary Central Nervous System Lymphoma: A Single-Arm, Phase Ib, Multicenter Study

Year: 2026

Type: article

Study design: Clinical Trial

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-25-3675

Authors: Kwang-Yu Chang, Ya-Ting Hsu, Shih-Sung Chuang, Chin-Fu Hsiao, Tai-Chung Huang, Ching-Yun Hsieh, Su-Peng Yeh, Wei-Li Ma, Ming-Chung Wang, Tsai-Yun Chen, Po-Ren Hsueh, Shang-Ju Wu

Institutions: National Health Research Institutes, National Cheng Kung University Hospital, National Cheng Kung University, Chi Mei Medical Center, National Taiwan University Hospital, China Medical University, China Medical University Hospital, Kaohsiung Chang Gung Memorial Hospital

Language: English

Topic: CNS Lymphoma Diagnosis and Treatment

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Health Research Institutes

Awards: G662209512, G84426309

OpenAlex ID: W7155159604

FWCI: 4.328

Cites: 48

Cited by: 1

Related to: